RACK1 inhibits the serum- and anchorage-independent growth of v-Src transformed cells  by Mamidipudi, Vidya et al.
FEBS 28460 FEBS Letters 567 (2004) 321–326RACK1 inhibits the serum- and anchorage-independent growth
of v-Src transformed cellsVidya Mamidipudi1, Betty Y. Chang1, Rachel A. Harte, Kelly C. Lee, Christine A. Cartwright*
Department of Medicine, Stanford University, Stanford, CA 94305, USA
Received 17 January 2004; revised 23 February 2004; accepted 26 March 2004
Available online 13 May 2004
Edited by Robert BaroukiAbstract Cancer cells are capable of serum- and anchorage-
independent growth, and focus formation on monolayers of
normal cells. Previously, we showed that RACK1 inhibits c-Src
kinase activity and NIH3T3 cell growth. Here, we show that
RACK1 partially inhibits v-Src kinase activity, and the serum-
and anchorage-independent growth of v-Src transformed cells,
but has no eﬀect on focus formation. RACK1-overexpressing v-
Src cells show disassembly of podosomes, which are actin-rich
structures that are distinctive to fully transformed cells.
Together, our results demonstrate that RACK1 overexpression
in v-Src cells partially reverses the transformed phenotype of the
cells. Our results identify an endogenous inhibitor of the
oncogenic Src tyrosine kinase and of cell transformation.
 2004 Federation of European Biochemical Societies.
Published by Elsevier B.V. All rights reserved.
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Cell adhesion1. Introduction
When regulated, the Src tyrosine kinase participates in di-
verse signaling pathways that control cell proliferation, dif-
ferentiation, adhesion and survival [1]. Deregulated Src is
oncogenic [2–5]. Thus, it is important to search for cellular
mechanisms that regulate Src. In doing so, we will learn about
mechanisms by which normal cells regulate their growth.
RACK1 (a homolog of the b subunit of G proteins) was
originally identiﬁed as an intracellular receptor for protein
kinase C (PKC) [6]. We identiﬁed RACK1 as a Src substrate
and an inhibitor of c-Src kinase activity and NIH 3T3 cell
growth [7–9]. However, it is not yet known what inﬂuence
RACK1 has on v-Src kinase activity or cell transformation. To
answer these questions, we stably expressed HA-RACK1 in v-
Src-transformed NIH 3T3 cells and analyzed the cells for v-Src
activity and for anchorage- or serum-independent growth and
focus formation on monolayers of normal cells, all capabilities
that fully transformed v-Src cells have and normal cells lack.
We observed that RACK1 expression partially inhibited the
anchorage- and serum-independent growth of v-Src trans-
formed cells, and in doing so, partially reversed their trans-
formed phenotype.* Corresponding author. Fax: +1-650-723-5488.
E-mail address: chris.cartwright@stanford.edu (C.A. Cartwright).
1 These authors contributed equally to the work.
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2.1. Cell culture
NIH 3T3 cells and NIH(pmvsrc/foc/EP)A1 [3] (gift from David
Shalloway, Cornell University, Ithaca, NY) were cultured in Dul-
becco’s modiﬁed Eagle’s medium (DMEM) (Mediatech, Herndon,
VA) supplemented with 10% calf serum (Sigma, St. Louis, MO), unless
otherwise stated.
2.2. Plasmids and transfection assays
Construction of pcDNA3-RACK1 and pcDNA3-HA-RACK1 (by
insertion of the inﬂuenza virus hemagglutinin (HA) tag into the BglII
site of pcDNA3-RACK1) has been previously described [7].
NIH(pmvsrc/foc/EP)A1 cells were transfected with 1 lg pcDNA3-HA-
RACK1 or pcDNA3 using Lipofectamine (Gibco-BRL) according to
the manufacturer’s protocol and as previously described [7]. Colonies
were selected for neomycin resistance with the addition of G418 (400
lg/ml) and subclones were examined for stable expression of HA-
RACK1 by immunoblotting with anti-RACK1 [2,7].
2.3. Antibodies
Src monoclonal antibody (MAb) 327 was produced from mouse
hybridoma cells [10]. MAbs that recognize RACK1, phosphotyrosine
(PY20), paxillin and focal adhesion kinase (FAK) were purchased
from Transduction Laboratories (Lexington, KY). Other commer-
cially available antibodies included Sam68 (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA), FAK Y397 and Y576 (BioSource
International, Camarillo, CA), rhodamine–phalloidin (Molecular
Probe, Eugene, OR) and cortactin (p80/85; Upstate Biotechnology,
Lake Placid, NY).
2.4. Immunoblot analysis and in vitro protein kinase assays
Lysate proteins or immunoprecipitates were resolved by SDS–
PAGE and analyzed by immunoblotting with the speciﬁed mouse
MAb or rabbit polyclonal antibody, as previously described [2,7–9].
Methods to evaluate the phosphorylating activity of Src by kinase
assays in vitro have also been described [2,7–9].
2.5. Cell growth assays
Growth rates of NIH(pmvsrc/foc/EP)A1 cells that were stably ex-
pressing HA-RACK1 or vector alone were analyzed as described [2,7].
Brieﬂy, 5 104 cells were suspended in DMEM supplemented with
0.2% FBS and seeded onto 35-mm diameter plates. Triplicate plates of
cells were counted daily with a hemocytometer from days 2 to 5. Cell
number was plotted versus time.
2.6. Agar colony assays
Agar colony assays were performed as described [2]. Brieﬂy,
NIH(pmvsrc/foc/EP)A1 cells that were stably expressing HA-
RACK1 or vector alone were suspended at varying densities in 1
ml of DMEM supplemented with 10% FBS and 0.33% Bacto-Agar
(Difco Laboratories, Detroit, MI). The cell suspension was added
to chilled, 35-mm diameter plates containing a 2 ml base of
DMEM supplemented with 10% FBS and 0.5% agar. After the
agar had solidiﬁed, plates were returned to a 37 C incubator.
Fourteen days later, colonies were counted on triplicate plates at
each dilution.blished by Elsevier B.V. All rights reserved.
Fig. 1. Eﬀect of HA-RACK1 expression of v-Src protein-kinase ac-
tivity. (A) v-Src transformed NIH 3T3 cells were transfected with
pcDNA3-HA-RACK1 or pcDNA3 and selected for neomycin resis-
tance as described in Section 2. Colonies were isolated and lysates
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Transformation assays were performed as described [2]. Brieﬂy, a
mixture of 104 NIH 3T3 cells and various numbers (50, 100 or 500) of
NIH(pmvsrc/foc/EP)A1 cells that were stably expressing HA-RACK1
or vector alone were suspended in DMEM supplemented with 5%
serum and seeded onto 35-mm diameter plates. The media were
changed every fourth day and the cells were rinsed, ﬁxed and stained
with crystal violet 21 days after plating. Foci were counted on triplicate
plates at each dilution.
2.8. Fluorescence microscopy
v-Src transformed NIH 3T3 cells that were stably expressing HA-
RACK1 or vector alone were grown overnight in DMEM supple-
mented with 10% FBS in Lab-Tek 8 well permanox chamber slides
(Nalgene Nunc International, Rochester, NY). Cells were ﬁxed in 4%
paraformaldehyde in PBS for 30 min, quenched twice in 0.1 M glycine
for 10 min and permeabilized in 0.4% saponin, 1% BSA and 5% goat
serum for 15 min [11]. For actin staining, cells were incubated with
rhodamine–phalloidin (33 nM; Molecular Probe, Eugene, OR) for 30
min in the dark. For cortactin staining, cells were incubated with anti-
cortactin (20 ng/ll) for 1 h, washed and incubated with FITC goat
anti-mouse IgG (1:100) for 30 min in the dark. Slides were mounted
with vectashield mounting medium (Vector Laboratories, Burlingame,
CA).containing 20 lg of total cellular protein were assayed for stable ex-
pression of HA-RACK1 by immunoblot analysis with anti-RACK1.
Lane 1: pcDNA3 transfected clone; Lanes 2 and 3: pcDNA3-HA-
RACK1-transfected clones. (B) Proteins were immunoprecipitated (ip)
with excess Src MAb 327 (lanes 1–3) or mouse IgG (lanes 4–6) from
lysates of HA-RACK1-expressing clones (lanes 2, 3, 5 and 6) or a
vector-transfected clone (lanes 1 and 4) that contained 100 lg of total
cellular protein. Immunoprecipitates were incubated with [c-32P]ATP,
MnCl2 and enolase for 10 min at 30 C in an in vitro protein kinase
assay. (C) v-Src transformed NIH 3T3 cells (lanes 1, 2, 7 and 8) or
parental NIH 3T3 cells (lanes 3–6 and 9–12) that were stably ex-
pressing HA-RACK1 (R) or vector alone (V) were lysed. Proteins from
lysate containing 200 lg of total cellular protein were precipitated with
anti-phosphotyrosine MAb PY20 and subjected to immunoblot anal-
ysis with anti-Sam68 (left upper panel), or precipitated with anti-
Sam68 and subjected to immunoblot analysis with MAb PY20 (right
panel). Left lower panel: proteins from lysate containing 10 lg of total
cellular protein were subjected to immunoblot analysis with anti-
Sam68. Data are representatives of three independent experiments.3. Results
3.1. RACK1 expression partially inhibits the tyrosine kinase
activity of v-Src
Previously, we found that RACK1 expression in NIH 3T3
cells inhibits c-Src kinase activity and cell growth [7–9]. To
determine whether RACK1 expression inﬂuences v-Src activity
and cell transformation, we transfected v-Src-transformed
NIH 3T3 cells with pcDNA3-HA-RACK1 and screened iso-
lated clones for stable expression of HA-RACK1 by subjecting
cell lysates to immunoblot analysis with anti-RACK1. We
selected two clones that were expressing the highest levels of
HA-RACK1 for further investigation (Fig. 1A, lanes 2 and 3,
upper band). We observed that HA-RACK1 was approxi-
mately one kDa larger than endogenous RACK1, as would be
predicted for a RACK1 protein containing nine additional
amino acids from a HA tag.
To assess the eﬀect of RACK1 overexpression on v-Src in
vitro kinase activity, we incubated Src or IgG immunopre-
cipitates of HA-RACK1- or vector-transfected v-Src clones
with [c-32P]ATP, MnCl2 and the exogenous substrate enolase,
and performed in vitro protein kinase assays (Fig. 1B). We
observed that Src activity, as measured by autophosphoryla-
tion or enolase phosphorylation, was lower in the two
HA-RACK1-expressing clones (lanes 2 and 3) than in the
vector-transfected clone (lane 1). Immunoblot analysis with
anti-Src showed that Src immunoprecipitates contained
equivalent amounts of Src protein (data not shown). As ex-
pected, proteins were not phosphorylated in control IgG im-
munoprecipitates (lanes 4–6). Thus, RACK1 overexpression
partially inhibited the in vitro tyrosine kinase activity of v-Src.
To assess the eﬀect of RACK1 expression on Src in vivo
kinase activity, we examined v-Src or NIH 3T3 clones that
were overexpressing HA-RACK for tyrosine phosphorylation
of Sam68, a mitotic-speciﬁc Src substrate [12,13] involved in
cell cycle regulation and RNA splicing (reviewed in [14])
(Fig. 1C). To do so, lysate proteins were ﬁrst precipitated with
an MAb that is speciﬁc for phosphotyrosine (PY20) and sub-
jected to immunoblot analysis with anti-Sam68 (left upper
panel). We observed that tyrosine phosphorylation of Sam68was lower in v-Src (lane 2) or NIH3T3 (lanes 5 and 6) clones
that were overexpressing RACK1 than in the corresponding
vector-transfected clones (lane 1 or 3 and 4, respectively).
Immunoblot analysis of cell lysate proteins with anti-Sam68
(lower panel) showed that similar amounts of Sam68 were
expressed in the HA-RACK1 and vector-transfected clones
(compare lanes 1 and 2 or 3–6). In a complementary approach,
we immunoprecipitated proteins with anti-Sam68 and immu-
noblotted with anti-phosphotyrosine and again observed
decreased tyrosine phosphorylation of Sam68 in the RACK1-
overexpressing cells (Fig. 1C, lanes 8, l1 and 12). Therefore,
RACK1 overexpression partially inhibited the in vivo tyrosine
kinase activity of Src, as measured by tyrosine phosphoryla-
tion of a mitotic-speciﬁc Src substrate.
3.2. RACK1 expression partially inhibits serum- and
anchorage-independent growth of v-Src transformed
NIH3T3 cells
One feature of cancer cells is their ability to grow in low
serum, presumably because of constitutive activation of
growth factor-dependent signaling pathways [1]. Thus, to as-
sess the eﬀect of RACK1 expression on serum-independent
growth of v-Src-transformed cells, we seeded equivalent
numbers of HA-RACK1- or vector-transfected v-Src cells in
Fig. 2. Eﬀect of HA-RACK1 expression on serum-independent growth
of v-Src-transformed cells. NIH(pmvsrc/foc/EP)A1 clones that were
stably expressing HA-RACK1 (2–4) or vector alone (1–2) were assayed
for cell growth rates in low serum. 5 104 cells were suspended in
DMEM supplemented with 0.2% FBS and seeded onto a 35-mm di-
ameter plate. Triplicate plates of HA-RACK1-expressing cells (closed
circles) or vector-transfected cells (open squares) were counted daily
from days 2 to 5. Data represent mean valuesS.E. from triplicate
plates at each time point. Data are representatives of two independent
experiments.
Table 1
Eﬀect of HA-RACK1 expression on anchorage-independent growth of
v-Src transformed NIH 3T3 cells
No. cells seeded/plate No. colonies/plate
Vector (1–2) HA-RACK(2–4)
50 1 1 0
500 36 6 7 2
1000 74 6 14 4
2000 175 10 32 4
5000 514 51 117 14
NIH(pmvsrc/foc/EP)A1 cells that were stably expressing HA-RACK1
(2–4) or vector alone (1–2) were suspended at various densities in 1 ml
of DMEM supplemented with 10% FBS and 0.33% agar. The cell
suspension was added to a chilled, 35-mm diameter plate containing a
2 ml base of DMEM supplemented with 10% FCS and 0.5% agar.
After the agar had solidiﬁed, triplicate plates at each dilution were
returned to a 37 C incubator. Colonies were counted 14 days later.
Data represent mean valuesS.E. from triplicate plates at each cell
dilution.
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We observed that the HA-RACK1-expressing v-Src cells grew
more slowly than the vector-transfected cells. After 5 days of
growth, there were approximately threefold fewer HA-
RACK1-expressing v-Src cells than vector-transfected cells.
Thus, RACK1 expression partially inhibited the serum-inde-
pendent growth of v-Src transformed cells.
The ability of cancer cells to grow without adhering to ex-
tracellular matrix proteins (anchorage-independent growth)
correlates closely with their ability to form malignant tumors
[15]. Anchorage-independent growth presumably allows the
cells to invade and metastasize, characteristics that distinguish
malignant from benign tumors. The ability of cancer cells to
form colonies in soft agar is a measure of their ability for
anchorage-independent growth. Thus, to assess the eﬀect of
RACK1 expression on anchorage-independent growth of v-
Src-transformed cells, we serially diluted HA-RACK1- or
vector-transfected v-Src cells, seeded the cells in DMEM sup-
plemented with 10% FBS and 0.33% agar, and counted colo-
nies 14 days later (Table 1). At all cell dilutions, we observed
ﬁvefold fewer colonies of HA-RACK1-expressing v-Src cells
than vector-transfected v-Src cells after 14 days of growth in
soft agar. Thus, RACK1 expression partially inhibited the
anchorage-independent growth of v-Src transformed cells. The
RACK1-overexpressing v-Src cells formed slightly smaller
colonies in soft agar than did the vector-transfected cells.
Another feature of v-Src transformed cells is their ability to
form foci on monolayers of normal cells, presumably because
the v-Src transformed cells are no longer contact inhibited [16].
Thus, to determine whether RACK1 expression inhibits the
focus-forming ability of v-Src-transformed cells, we seeded a
mixture of 104 NIH 3T3 cells and various numbers of HA-RACK1- or vector-transfected v-Src cells in DMEM supple-
mented with 10% FBS, and counted foci 21 days later. At all
cell dilutions, we observed a similar number of foci formed by
the HA-RACK1-expressing as the vector-transfected v-Src
clones (data not shown). Thus, RACK1 expression had no
apparent eﬀect on the ability of v-Src transformed cells to form
foci on monolayers of normal cells.
3.3. RACK1 expression modulates tyrosine phosphorylation of
focal adhesion proteins
The reduced ability of RACK1-overexpressing cells to
grow in soft agar suggested that the cells require anchorage
to extracellular matrix. Adhesion to extracellular matrix is
mediated by integrins [1], and b integrins interact with
RACK1 [17]. Upon binding to extracellular matrix proteins,
integrin receptors are activated and induce tyrosine phos-
phorylation of FAK and paxillin; proteins whose tyrosine
phosphorylation is important for integrin-mediated cell ad-
hesion [1,18,19]. Thus, to explore potential mechanisms
whereby RACK1 overexpression inhibits the ability of v-Src
cells to grow in anchorage-independent conditions, we ex-
amined the HA-RACK1-expressing v-Src cells or NIH 3T3
cells for tyrosine phosphorylation of paxillin (Fig. 3A) and
FAK (Fig. 3B). To do so, we ﬁrst immunoprecipitated
proteins with anti-phosphotyrosine and immunoblotted with
anti-FAK or paxillin (left upper panels). We observed that
tyrosine phosphorylation of both paxillin and FAK was
higher in the RACK1-overexpressing v-Src (lane 2) and NIH
3T3 (lanes 5 and 6) cells than in the vector-transfected cells
(lane 1 or 3 and 4, respectively). Immunoblot analysis of cell
lysates with anti-paxillin or anti-FAK (lower panels) dem-
onstrated that equivalent amounts of paxillin or FAK were
expressed in the HA-RACK1 and vector-transfected clones
(compare lanes 1 and 2 or 3–6). In a complementary ap-
proach, we immunoprecipitated proteins with anti-paxillin or
anti-FAK and immunoblotted with anti-phosphotyrosine
(Figs. 3A and B, respectively; lanes 7–12), and again ob-
served increased tyrosine phosphorylation of paxillin and
FAK in the RACK1-overexpressing cells. Thus, RACK1
overexpression increased the tyrosine phosphorylation of
paxillin and FAK; proteins whose tyrosine phosphorylation
is important for integrin-mediated cell adhesion [18–22].
Fig. 4. Eﬀect of HA-RACK1 expression on the actin cytoskeleton. v-
Src transformed NIH 3T3 cells that were stably expressing HA-
RACK1 (right panels) or vector (left panels) were ﬁxed in 4%
paraformaldehyde in PBS for 30 min, quenched twice in 0.1 M gly-
cine for 10 min and permeabilized in 0.4% saponin, 1% BSA and 5%
goat serum for 15 min. Cells were stained with rhodamine–phalloidin
(upper panels) or antibody to cortactin (lower panels) for 30 min in
the dark, as described in Section 2. Data are representatives of three
independent experiments.
Fig. 3. Eﬀect of HA-RACK1 expression on the tyrosine phosphory-
lation of paxillin and FAK. (A–D) v-Src transformed NIH 3T3 cells
(lanes 1, 2, 7 and 8) or parental NIH 3T3 cells (lanes 3–6 and 9–12) that
were stably expressing HA-RACK1 (R) or vector alone (V) were lysed.
(A and B) Proteins from lysate containing 200 lg of total cellular
protein were precipitated with anti-phosphotyrosine and subjected to
immunoblot analysis with anti-paxillin or FAK (left upper panels), or
precipitated with anti-paxillin or FAK and subjected to immunoblot
analysis with anti-phosphotyrosine (right panels). Left lower panels:
proteins from lysate containing 10 lg of total cellular protein were
subjected to immunoblot analysis with anti-paxillin or FAK. (C and
D) Upper panels: proteins precipitated with anti-FAK from lysate
containing 200 lg of total cellular protein were subjected to immu-
noblot analysis with FAK antibody that speciﬁcally recognizes phos-
phorylated Y397 or Y576. Lower panels: proteins from lysate
containing 10 lg of total cellular protein were subjected to immuno-
blot analysis with anti-FAK. Data are representatives of three inde-
pendent experiments.
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Y397 [19] and this is critical to subsequent downstream sig-
naling events involved in cell adhesion. One downstream event
involves Src, which binds with high aﬃnity via its SH2 domain
to pY397 of FAK, and then phosphorylates other sites on
FAK. A major Src phosphorylation site on FAK is Y576,
which lies in the activation loop of the catalytic domain [23–
25]. Thus, to assess RACK1’s inﬂuence on phosphorylation of
speciﬁc tyrosines in FAK, we subjected FAK immunoprecip-
itates to immunoblot analysis with antibodies that recognize
phosphorylated Y397 or Y576. We observed that tyrosine
phosphorylation of FAK at the autophosphorylation site was
increased (Fig. 3C, upper panel), whereas tyrosine phosphor-
ylation of FAK at a major Src phosphorylation site was de-
creased (Fig. 3D, upper panel) in the RACK1-overexpressing
cells. This observation was consistent with previous work
showing that FAK autophosphorylation at Y397 is indepen-
dent of Src kinase activity [26].
3.4. RACK1 expression alters cytoskeletal features of v-Src
transformed cells
A rapid consequence of activation of v-Src is the replace-
ment of organized actin stress ﬁbers and focal adhesions (into
which the actin ﬁbers are tethered) with actin-rich ring struc-
tures called podosomes [27,28]. While podosomes containsimilar proteins to those found in focal adhesions, their ar-
chitecture is distinct in that podosomes do not have actin stress
ﬁbers tethered to them, but rather have a peculiar structure
with an actin core [29] surrounded by a membrane domain
enriched in integrins and adaptor proteins such as vinculin and
paxillin. To assess the inﬂuence of RACK1 expression on the
actin cytoskeleton in v-Src transformed cells, we stained
RACK1-overexpressing and vector-transfected v-Src cells with
phalloidin (Fig. 4). We observed numerous dense, actin-rich,
ring structures in v-Src transformed cells that had the ap-
pearance of podosomes (upper left panel). Additional staining
for cortactin (lower left panel), an F-actin bundling protein
that distinctly localizes to podosomes [28,30], conﬁrmed that
the structures were podosomes. We observed a striking disas-
sembly and disappearance of podosomes in the RACK1-
overexpressing cells (right panels). However, we did not detect
an increase in actin stress ﬁbers or focal-adhesion structures
(vinculin or paxillin) in v-Src cells that were stably or tran-
siently overexpressing RACK1 (data not shown). Thus,
RACK1 overexpression in v-Src cells partially disassembled
actin cytoskeleton features that are distinctive to fully trans-
formed cells (podosomes), but did not reassemble cytoskeleton
features that are characteristic of normal cells.4. Discussion
This study shows that RACK1 expression partially inhibits
v-Src kinase activity (Fig. 1) and the serum- and anchorage-
independent growth of v-Src transformed cells (Fig. 2 and
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transformed phenotype of the cells. These ﬁndings extend our
previous observations that RACK1 expression inhibits c-Src
kinase activity and the growth of NIH 3T3 cells [7]. They
provide new information about the inﬂuence of RACK1 on
cell transformation by v-Src.
The reduced ability of RACK1-overexpressing v-Src cells to
grow in low serum (Fig. 2) suggests that RACK1 may function
in growth factor-dependent signaling pathways. Previously, we
showed that treatment of cells with platelet-derived growth
factor (PDGF) induces the association of Src and RACK1 and
the tyrosine phosphorylation of RACK1 by Src [8]. Thus,
RACK1 appears to function, in part, by inhibiting the PDGF
receptor-Src signaling pathway. RACK1 also functions in the
insulin-like growth factor I receptor (IGF-IR) dependent sig-
naling pathway [31]. In both pathways, RACK1 partially in-
hibits cell growth by prolonging the G0=G1 phase of the cell
cycle [7,31].
The ﬁnding that RACK1-overexpressing v-Src cells formed
slightly smaller colonies than did the vector-transfected cells is
probably a reﬂection of the slightly slower growth rates of the
RACK1-overexpressing cells observed in 10% serum (data not
shown). However, this would not account for the ﬁvefold de-
crease in ability of the RACK1-overexpressing v-Src cells to
form colonies in soft agar (Table 1). Thus, RACK1 overex-
pression signiﬁcantly reduces the ability of v-Src transformed
cells to grow in anchorage-independent conditions.
v-Src transformed cells form foci on monolayers of normal
cells, presumably because the cells are no longer constrained
by density-dependent inhibition of cell division (contact inhi-
bition) [16]. Our ﬁnding that RACK1 expression in v-Src
transformed cells did not aﬀect focus formation suggests that
overexpression of RACK1 is not suﬃcient to override the
mechanism by which v-Src drives cell division forward despite
increasing cell density, or that the mechanism is independent of
v-Src’s interaction with RACK1.
Emerging evidence suggests a role for RACK1 in integrin-
dependent cell adhesion [31–33]. RACK1 overexpression in
untransformed cells is known to increase the number of actin
stress ﬁbers and focal adhesions, enhance cell spreading and
inhibit cell migration. RACK1 appears to mediate cell mi-
gration via its interaction with PKC [32] and integrin-depen-
dent cell adhesion via its interaction with Src [33]. Consistent
with these observations, we ﬁnd that overexpression of
RACK1 in v-Src transformed cells strikingly reduces the
ability of the cells to grow in suspension (Table 1). However,
overexpressing RACK1 in Src-transformed cells was not suf-
ﬁcient to increase formation of actin stress ﬁbers or focal ad-
hesion structures (vinculin or paxillin), as occurs when
RACK1 is overexpressed in untransformed cells. Thus,
RACK1’s inhibitory inﬂuence on v-Src activity is not powerful
enough to completely reverse the transformed phenotype of
the cells and restore a normal phenotype.
RACK1 overexpression in NIH 3T3 cells that express ele-
vated levels of IGF-IR also induces tyrosine phosphorylation
of paxillin and FAK [31]. The mechanism is thought to involve
binding of RACK1 to b integrins and activated PKC [34].
Consequently, FAK autophosphorylates, recruits paxillin to
the complex, and directs the tyrosine phosphorylation of
paxillin [17,18, reviewed in]. Expression of various Src mole-
cules in ﬁbroblasts lacking other Src family kinases revealed
that FAK can autophosphorylate at Y397 independently ofSrc [26]. However, Src kinase activity is required for phos-
phorylation of additional sites on FAK and for other integrin-
directed functions, including cell spreading. Our observations
that RACK1 overexpression in v-Src cells results in increased
tyrosine phosphorylation of paxillin and FAK (at the auto-
phosphorylation site), and decreased tyrosine phosphorylation
of FAK at a major Src phosphorylation site (Fig. 3), are
consistent with these ﬁndings.
RACK1’s inﬂuence on normal cellular responses is broad-
reaching, aﬀecting biologic functions as diverse as those that
regulate cell growth [7], adhesion [31–33], migration [32,33],
protrusion [33], death [35,36] and cell-cell interactions [37].
Some of the RACK1 eﬀects (e.g., cell protrusion) appear to be
due to RACK1’s inﬂuence on Src kinase activity, others (e.g.,
cell migration) do not. Together, the ﬁndings signify the
powerful and pervasive inﬂuence that RACK1 has on a wide
array of signals that regulated distinct cellular functions.
In summary, we have shown that RACK1 overexpression
partially inhibits anchorage- and serum-independent growth of
v-Src-transformed cells and alters cytoskeletal features of the
transformed cells. We believe that RACK1 is an important Src
substrate that signals downstream of growth factor receptor
tyrosine kinases and is involved in the regulation of Src activity
and cell growth. The signiﬁcance of these ﬁndings is that en-
dogenous inhibitors of oncogenic tyrosine kinases are poten-
tially tumor suppressors; they represent exciting new targets
for cancer therapy.
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